LY3300054

anti-PD-L1 antibody · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3300054, covering 2024-09-27 to 2024-09-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors [Phase 1]

See pricing